🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📰 Extra! Extra!📰 In the latest article for Drug Target Review , our CEO Roman Thomas describes how DISCO Pharmaceuticals GmbH uses its disruptive technology to map the surface proteins of cancer cells in search of novel drug targets. Read the full article here 👉 bit.ly/3W1QK0x

Our CEO, Roman Thomas, spoke🎙to Janelle Hart at Citeline , following his recognition as one of #InVivosRisingLeaders2024. Read the article to learn about our target 🎯discovery platform technology and its potential to redefine cancer #drugdiscovery: bit.ly/3Wx6lXj

On #WorldLungCancerDay, we want to raise awareness of the most aggressive form of lung cancer: #SmallCellLungCancer (#SCLC). At DISCO Pharmaceuticals GmbH, we have completed the first-ever mapping of the SCLC #surfaceome. Learn more here👉discopharma.de #WLCD2024

Sometimes you need to retreat from the spotlight and relax. The DISCO team sashayed its way to Karlsruhe, Germany to connect, reflect and fortify our #teambuilding skills.

There’s lots of optimism as noted in Melanie Senior's recent article published in nature's Biotechnology. Alongside other notable events, our €20m seed financing suggests the sector is headed in the right direction. Read the full article here 👉 go.nature.com/4dyZQZE

Our Head of Technology & DISCO Zürich, Emanuela Tschudy-Milani, will be attending the Festival of Biologics in Basel🗻from 15-17 Oct. Reach out to connect with Emanuela onsite to learn more about our groundbreaking #surfaceome mapping technology. #FestivalofBiologics2024

Join DISCO Pharmaceuticals GmbH in Dresden, 🇩🇪 for the 23rd Human Proteome World🌍Congress from 20-24 October. 💬Connect with us onsite to explore how DISCO is transforming #cancer care by expanding the molecular target🎯space with our cutting-edge #surfaceome mapping technology🦠. #HUPO2024 #EuPA

Meet DISCO Pharmaceuticals GmbH at Hanson Wade 's #WorldADC in sunny☀San Diego⛱ from 4-7 Nov to learn more about we are overcoming the challenges in ADC development using our disruptive #surfaceome mapping technology. #AntibodyDrugConjugates

🎙️In this podcast to mark #LungCancerAwarenessMonth, Optimum’s Richard Staines speaks to Roman Thomas, CEO and founder of DISCO Pharmaceuticals GmbH, on breakthroughs that have improved patient outcomes, and the company’s efforts to help develop new therapies with its “surfaceome” technology.